This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Morrell, J. Search for Related Content Social Bookmarking                         What's this?

Initiating antiplatelet therapy in diabetes: a PCO view

Department of Cardiology, Conquest Hospital, The Ridge, St. Leonards-on-Sea, East Sussex, TN37 7RD, UK, drjmmorrell{at}aol.com

Antiplatelet therapy has a role in the primary and secondary prevention of serious vascular events, especially in high-risk patients, including people with diabetes. This review considers the evidence and guideline recommendations for initiating antiplatelet therapy in people with diabetes with and without vascular disease. It concludes that, for diabetic patients with coronary heart disease, stroke or peripheral vascular disease, an antiplatelet agent (e.g. aspirin 75 mg per day or clopidogrel 75 mg per day) should be given routinely and continued in the long term. For diabetic patients with acute coronary syndromes, the addition of clopidogrel (75 mg daily) to usual therapy should be considered. For primary prevention, aspirin (75 mg) should be considered for all diabetic patients with well controlled hypertension and a 20% risk of developing coronary disease over 10 years.

Key Words: diabetes • platelets • vascular disease • aspirin • clopidogrel.

References

• Rayner M., Petersen S., Buckley C., Press V. Coronary Heart Disease Statistics: Diabetes Supplement. London: British Heart Foundation, 2001.
• Diabetes UK Fact sheet no. 3 - diabetes: cost and complications. http://www.diabetes.org.uk/infocentre/fact/fact3.htm.
• Haffner SM, Lehto S., Ronnemaa T., Pyorala K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.[Abstract/Free Full Text]
• Evans JMM, Wang J., Morris AD Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross-sectional and cohort studies. BMJ 2002;324:939-42.[Abstract/Free Full Text]
• Jorgensen H., Nakayama H., Raaschou HO, Olsen TS Stroke in patients with diabetes. The Copenhagen Stroke Study. Stroke 1994;25:1977-84.[Abstract]
• Sanmuganathan PS, Ghahramani P., Jackson PR, Wallis EJ, Ramsay LE Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 2001;85:265-71.[Abstract/Free Full Text]
• Hansson L., Zanchetti A., Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71-86.[Abstract/Free Full Text]
• U.S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 2002;136:157-60.[Abstract/Free Full Text]
• Pearson TA, Blair SN, Daniels SR et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Consensus Panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 2002;106:388-91.[Free Full Text]
• Scottish Intercollegiate Guidelines Network. Guideline 55: Management of Diabetes. Edinburgh: SIGN, 2001. www.sign.ac.uk/guidelines/fulltext/55
• Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998;19:1434-503.[Free Full Text]
• Wood D., Durrington P., Poulter N. et al. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998;80(suppl 2):S1-S29.[Free Full Text]
• Bhatt DL, Marso SP, Hirsch AT et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002; 90:625-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002;287: 2570-81.[Abstract/Free Full Text]
• Vinik AI, Erbas T., Park TS, Nolan R., Pittenger GL Platelet dysfunction in Type 2 diabetes. Diabetes Care 2001;24:1476-85.[Abstract/Free Full Text]
• CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.[Abstract/Free Full Text]
• American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2000;23(suppl 1):S33-S49.
• Smith Jr SC, Blair SN, Bonow RO et al. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 2001;104:1577-9.[Free Full Text]
• Braunwald E., Antman EM, Beasley JW et al. Management of Patients with Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction Update. ACC/AHA 2002 Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). http://www.acc.org/clinical/guidelines/unstable/incorporated/index.htm
• Scottish Intercollegiate Guidelines Network. Guideline No. 36. Antithrombotic Therapy. Edinburgh: SIGN, 1999.www.sign.ac.uk/guidelines/fulltext/36
• Anticoagulants, antithrombotics and fibrinolytics: Asasantin retard and Persantin retard. MIMS 2002;July:Section 2F.
• Diener HC, Cunha L, Forbes S et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Bertrand ME Press conference press release: Guidelines of the European Society of Cardiology concerning acute coronary syndromes without ST-segment elevation. http://www.escardio.org/VPO/pcdetails/ESC%20Guidelines/PC%20Bertrand.pdf
• Dyslipidaemia Advisory Group on behalf of the scientific committee of the National Heart Foundation of New Zealand. 1996 National Heart Foundation clinical guidelines for the assessment and management of dyslipidaemia. N Z Med J 1996;109:224-31.[Web of Science][Medline] [Order article via Infotrieve]
• Anderson KM, Odell PM, Wilson PWF, Kannel WB Cardiovascular disease risk profiles. Am Heart J 1991;121:293-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Stevens RJ, Kothari V., Adler AI, Stratton IM, United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci 2001;101:671-9 (erratum in Clin Sci 2002;102:679).
• Testing Times: A Review of Diabetes Services in England and Wales. London: The Audit Commission, 2001.
• Department of Health. National Service Framework for Diabetes. London: Stationery Office, 2003. www.doh.gov.uk/nsf/diabetes/
• Department of Health. National Service Framework for Coronary Heart Disease. London: Stationery Office, 2000. www.doh.gov.uk/nsf/coronary/

The British Journal of Diabetes & Vascular Disease, Vol. 3, No. 5, 349-353 (2003)
DOI: 10.1177/14746514030030050701


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Morrell, J. Search for Related Content Social Bookmarking                         What's this?